| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Verona Pharma plc Sponsored ADR$106.91
+0.06 (+0.06%)
C 40Pipeline Score Overvalued Pharma · Commercial
Market Cap
9.19 B
EPS
-1.02
P/E Ratio
-
Value Trade
200.07 M
0.15 %
Week
0.45 %
1 Month
17.47 %
3 Month
102.6 %
6 Month
1,554.95 %
5 Year
691.93 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
1.87 M
52 Week Range
31.09 - 106.93
% held by Insiders
9.9 %
% held by Institutions
76.31 %
Enterprise Value
9.00 B
Total Shares
85.99 M
Short %
10.97 %
Float Shares
78.31 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C40
Pipeline Score $1.5B
Pipeline ValueOvervalued
Valuation Signal4
Drugs Scored0.2x
rNPV / MCap Top 57%
Small Cap (rank 391 of 906)
Percentile RankVerona Pharma plc Sponsored ADR carries a moderate pipeline score (40/100), with $2.3B risk-adjusted pipeline value, led by Sotrovimab in COVID-19 (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sotrovimab Small molecule | COVID-19 | Phase 3 | NCT05321394 | 62% | $1.8B | COMPLETED | 536 | - | - | Oct 29, 2023 | - | Nov 7, 2023 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Ohtuvayre | COPD | Phase 3 | 2025-09-16 | statistically significant and clinically meaningful improvements in lung function Read More | Verona Pharma to Present Additional Analyses of the Phase 3 ENHANCE Studies in COPD at ERS International Congress 2025 Read More | |
Ohtuvayre | COPD | Phase 3 | 2025-09-16 | statistically significant and clinically meaningful improvements in lung function Read More | Verona Pharma to Present Additional Analyses of the Phase 3 ENHANCE Studies in COPD at ERS International Congress 2025 Read More | |
Ohtuvayre | COPD | Phase 3 | 2025-09-16 | statistically significant and clinically meaningful improvements in lung function Read More | Verona Pharma to Present Additional Analyses of the Phase 3 ENHANCE Studies in COPD at ERS International Congress 2025 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in VRNA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
VRNA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How VRNA ranks across every disease it competes inCompetitive Position is a premium feature
See how VRNA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial